Mitomycin C (MMC), Anticancer and antibiotic agent (ab120797)
Key features and details
- Anticancer and antibiotic agent
- CAS Number: 50-07-7
- Purity: > 99%
Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Streptomyces sp.
製品の概要
-
製品名
Mitomycin C (MMC), Anticancer and antibiotic agent -
製品の詳細
Anticancer and antibiotic agent -
別名
- MMC
-
精製度
> 99% -
CAS 番号
50-07-7 -
構造式
製品の特性
-
体系名
(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
-
分子量
334.33 -
分子式
C15H18N4O5 -
PubChem 登録番号
5746 -
保存方法
Store at +4°C. The product can be stored for up to 12 months. -
溶解性
Soluble in DMSO to 100 mM
-
使用に関する注意
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES 線形表記
CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N -
由来
Streptomyces sp.
-
研究分野
関連製品
-
Alternative Versions
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab120797の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
特記事項 |
---|
Functional Studies
Use at an assay dependent concentration. |
画像
-
2D chemical structure image of ab120797, Mitomycin C (MMC), Anticancer and antibiotic agent
-
Functional assays: Caspase 8 (active) FITC Staining Kit (ab65614)
Active caspase 8 in control Jurkat cells (10e6/mL) or cells treated for five hours with 10 ug/mL Cyclohexamide (CHX) (ab120093) or four hours with 25 ug/mL Mitomycin C (MitoC) (ab120797). Background signal subtracted, duplicates; +/- SD.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
参考文献 (7)
ab120797 は 7 報の論文で使用されています。
- Sinha S et al. Dynamically Crosslinked Poly(ethylene-glycol) Hydrogels Reveal a Critical Role of Viscoelasticity in Modulating Glioblastoma Fates and Drug Responses in 3D. Adv Healthc Mater 12:e2202147 (2023). PubMed: 36239185
- Azimi Lamouty M et al. Fabrication of Cell-Laden AME-Loaded Collagen-Based Hydrogel Promotes Fibroblast Proliferation and Wound Healing In Vitro. Cell J 25:255-263 (2023). PubMed: 37210646
- Huang CJ et al. Improvement of wound healing by capsaicin through suppression of the inflammatory response and amelioration of the repair process. Mol Med Rep 28:N/A (2023). PubMed: 37387413
- Chiou AE et al. Fluorescent Silica Nanoparticles to Label Metastatic Tumor Cells in Mineralized Bone Microenvironments. Small 17:e2001432 (2021). PubMed: 32462807
- Ruggiano A et al. The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. Cell Rep 37:110080 (2021). PubMed: 34879279
- Li J et al. A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma. Mol Med Rep 16:7105-7111 (2017). PubMed: 28901423
- Massee M et al. Type I and II Diabetic Adipose-Derived Stem Cells Respond In Vitro to Dehydrated Human Amnion/Chorion Membrane Allograft Treatment by Increasing Proliferation, Migration, and Altering Cytokine Secretion. Adv Wound Care (New Rochelle) 5:43-54 (2016). PubMed: 26862462